Pulse Biosciences (PLSE) announced the enrollment of the first patient in its NANOCLAMP AF study for the treatment of atrial fibrillation. The successful first procedure was completed at St. Helena Hospital in St. Helena, California, with the nPulse Cardiac Surgical System following its recent FDA IDE approval.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLSE: